Session » Rheumatoid Arthritis – Clinical Aspects V: Predicting Treatment Response

Date: Tuesday, November 7, 2017

Time: 4:30PM-6:00PM

Meeting: 2017 ACR/ARHP Annual Meeting

Abstract Number: 2861

Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study

Abstract Number: 2862

Diverse Disease Activity Measures Demonstrate That the Routine Assessment of Patient Index Data with 3 Measures (Rapid-3) Assesses Only Non Inflammatory Components of Disease and Should Not be Utilized in a Treat to Target Strategy in Rheumatoid Arthritis

Abstract Number: 2863

Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal

Abstract Number: 2864

Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time

Abstract Number: 2865

The Utility and Limitations of Serum C-Reactive Protein in Appraising Synovial Inflammation

« View all sessions from this meeting